<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354133</url>
  </required_header>
  <id_info>
    <org_study_id>A 121/06</org_study_id>
    <nct_id>NCT00354133</nct_id>
  </id_info>
  <brief_title>Controlled Trial of Deep Brain Stimulation in Early Patients With Parkinson's Disease</brief_title>
  <official_title>The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Parkinson Study Group (GPS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Parkinson Study Group (GPS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinsons' disease is one of the most disabling chronic neurological diseases. It can be
      treated sufficiently until motor complications with fluctuations of mobility and dyskinesias
      develop. The quality of life and the social and occupational functioning is relentlessly
      deteriorating with longer disease duration once the complications of conservative therapy
      develop. High-frequency stimulation of the subthalamic nucleus especially improves the motor
      complications of Parkinson's disease and preliminary data suggest that also the quality of
      life and psychosocial handicap are improved. So far this therapy is only used for patients
      which have already undergone personal, professional and social degradation due to motor
      complications of the disease. The aim of this study is to assess the use of this therapy in
      earlier stages of the disease, when motor complications have just developed and before
      patients are significantly affected in their social and occupational functioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized either to medical treatment or subthalamic stimulation. The
      observation period is 2 years. The primary outcome criterium: PDQ-39.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Unified Parkinson's disease Rating Scale (UPDRS) part III, Change in the number of hours per day in the &quot;best&quot;-state,Frequency and severity of &quot;best&quot;state dyskinesias,Sleeping-hours per day,Changes in gait and speech,</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS II and VI, SCOPA-PS, BDI, MADRS, BPRS, Mattis Dementia Scale,Ardouin Behaviour Scale, Starkstein-Apathy Scale, professional fitness, SF-36,pain (VAS), clinical global impression (CGI-GI)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and severity of therapy related adverse events of medication or DBS, Change in medication (L-DOPA equivalents)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Deep brain stimulation Nucleus subthalamicus and best medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kinetra and Soletra (neurostimulator, Medtronic)</intervention_name>
    <description>Arm I: Implantation of stimulation electrodes in the STN and best medical treatment Arm II: Best medical treatment only</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's Disease

          -  Hoehn and Yahr stage ≤ 2.5 in the best &quot;on&quot;med condition

          -  Disease duration &gt; 4 years

          -  Presence of fluctuations and/or dyskinesias for no more than 3 years

          -  One of the two following forms of impairment:

          -  Impairment in activities of daily living (UPDRS II &gt; 6) due to PD-symptoms despite
             medical treatment in the &quot;worst&quot; condition or

          -  Impairment of social and occupational functioning (measured with a modified SOFAS) due
             to PD-symptoms despite medical treatment (51-80%)

          -  PDQ-39 completed

          -  Written informed consent

          -  For the patients in France a social security number is required

        Exclusion Criteria

          -  Major depression with suicidal thoughts (Beck Depression Inventory &gt; 25)

          -  Dementia (Mattis Score ≤ 130)

          -  Acute psychosis

          -  Need for nursing care

          -  Any medical or psychological problems which may interfere with a smooth conduction of
             the study protocol (e.g. cancer with a limited life expectancy)

          -  Drug or alcohol addiction

          -  Surgical contraindications

          -  Fertile women not using adequate contraceptive methods

          -  Women who are pregnant or breast feeding

          -  Illiteracy or insufficient language skills (German or French) to complete the
             questionnaires

          -  Simultaneous participation in another clinical trial except that other trial does not
             affect the Earlystim study as approved and documented by the steering committee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenther Deuschl, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Christian-Albrechts-University Kiel, Schittenhelmstr. 10, D 24105 Kiel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Agid, Pr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitié- Salpêtrière, Fédération des Maladies du Système Nerveux, 47-83 Boulevard de l´Hôpital, F- 75651 Paris Cedex 13</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michallon Hospital, CHU Grenoble, Service de Neurologie, BP217</name>
      <address>
        <city>Grenoble Cedex</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie C, Hôpital Neurologique et neurochirurgical Pierre Wertheimer , 59 Bd Pinel 69677 BRON Cedex</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier La Timone, Service de neurologie et pathologie du mouvement,Boulevard Jean Moulin</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Hôpital Nord Laënnec Boulevard Jacques-Monod - Saint-Herblain</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC, CHU Pitié-Salpêtrière, 47-83 Bd de l'Hôpital</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Milétrie, Tour Jean Bernard, 350 Av Jacques Cœur, BP 577</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire de Rouen, Charles Nicolle, bat. DV, 1 rue de Germont</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation Clinique, Pavillon Riser, Hôpital Purpan,Place du Dr Baylac TSA 40031</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Neurologie, Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik der Universität, Moorenstr. 5</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Freiburg, Breisacher Str. 64</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik der Universität Heidelberg, Neuenheimerfeld 400</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena-Klinik, Kassel, Klinikstrasse 16</name>
      <address>
        <city>Kassel</city>
        <zip>34128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Schittenhelmstr. 10</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München Neurologische Klinik und Poliklinik - Großhadern, Marchioninistr. 15</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Klinik für Neurochirurgie, Hoppe-Seyler-Str.3</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-parkinson.de/</url>
    <description>(German Research Collaboration, funded by the German Ministry of Research)</description>
  </link>
  <link>
    <url>http://www.kks-mr.de</url>
    <description>(Homepage Coordination Center for Clinical Studies to STN Study, Language: German)</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>January 27, 2012</last_update_submitted>
  <last_update_submitted_qc>January 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>PDQ-39</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

